Cost-effectiveness of protease inhibitor based regimens for chronic hepatitis C: a systematic review of published literature (Q38206573)

31 August 2017

title

Cost-effectiveness of protease inhibitor based regimens for chronic hepatitis C: a systematic review of published literature (English)

1 reference

31 August 2017

1 reference

1 reference

1 reference

1 reference

Ramón San Miguel

1 reference

31 August 2017

Vicente Gimeno-Ballester

series ordinal

1 reference

31 August 2017

Javier Mar

series ordinal

1 reference

31 August 2017

publication date

23 April 2014

1 reference

Expert Review of Pharmacoeconomics & Outcomes Research

31 August 2017

published in

1 reference

31 August 2017

1 reference

31 August 2017

1 reference

31 August 2017

page(s)

387-402

1 reference

Global epidemiology of hepatitis C virus infection

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2014.906307

The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2014.906307

Recognizing and preventing death from compensated cirrhosis in the community

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2014.906307

Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2014.906307

The impact of hepatitis C virus infection on work absence, productivity, and healthcare benefit costs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2014.906307

Hepatitis C: cost of illness and considerations for the economic evaluation of antiviral therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2014.906307

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2014.906307

IL28B in hepatitis C virus infection: translating pharmacogenomics into clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2014.906307

Distributive justice and the arrival of direct-acting antivirals: Who should be first in line?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2014.906307

Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2014.906307

Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2014.906307

Viral hepatitis: Cost-effectiveness of direct-acting antivirals for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2014.906307

The impact of timing and prioritization on the cost-effectiveness of birth cohort testing and treatment for hepatitis C virus in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2014.906307

Cost-effectiveness analysis of triple therapy with protease inhibitors in treatment-naive hepatitis C patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2014.906307

Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2014.906307

Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2014.906307

Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in previously untreated chronic hepatitis C genotype 1 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2014.906307

Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2014.906307

New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2014.906307

Cost-effectiveness analysis of boceprevir for the treatment of chronic hepatitis C virus genotype 1 infection in Portugal

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2014.906307

Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2014.906307

Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2014.906307

Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in treatment-experienced chronic hepatitis C genotype 1 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2014.906307

Boceprevir for untreated chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2014.906307

Telaprevir for previously untreated chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2014.906307

Factors that predict response of patients with hepatitis C virus infection to boceprevir

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2014.906307

Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2014.906307

Empirically calibrated model of hepatitis C virus infection in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2014.906307

Boceprevir for previously treated chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2014.906307

Telaprevir for retreatment of HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2014.906307

Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2014.906307

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2014.906307

A systematic review of the cost-effectiveness of peginterferon alfa-2b in the treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2014.906307

Estimates of the Cost-Effectiveness of a Single Course of Interferon-α2b in Patients with Histologically Mild Chronic Hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2014.906307

Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2014.906307

Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2014.906307

Structural frameworks and key model parameters in cost-effectiveness analyses for current and future treatments of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2014.906307

Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2014.906307

Modeling good research practices--overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2014.906307

Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2014.906307

Sofosbuvir for previously untreated chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2014.906307

Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2014.906307

Simeprevir for the treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2014.906307

Modeling using Discrete Event Simulation: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.2014.906307

10.1586/14737167.2014.906307

21 January 2018

Identifiers

DOI

1 reference

31 August 2017

1 reference